Skip to main content
. 2008 Nov 20;26(33):5360–5367. doi: 10.1200/JCO.2008.17.4284

Fig 3.

Fig 3.

Correlation of tumor genotype (KIT exon 9–mutant, KIT exon 11–mutant, or wild-type tumors), imatinib dose (400 mg [IM400] v 800 mg [IM800]), and time to progression and overall survival for patients with CD117-positive gastrointestinal stromal tumors.